Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis
https://doi.org/10.14412/2074-2711-2023-6-142-145
Abstract
Currently, more than 15 molecules are already approved for the treatment of multiple sclerosis, and sometimes physicians encounter problems selecting a drug for therapy when considering patients with the initial equivalent characteristics. When selecting a drug, it is important to consider not only the efficacy and safety of the drug, but also the possibility of further therapy after discontinuation of the initially selected drug. This paper discusses the results of clinical trials on the efficacy and safety of ofatumumab and its potential advantages over other anti-CD20 agents.
Supporting agencies: This article has been supported by Novartis
About the Author
E. V. Popova
City Clinical Hospital Twenty-Four, Moscow Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
Ekaterina Valerievna Popova
Moscow 10, Pistsovaya St., Moscow 127015
Competing Interests:
The conflict of interest has not affected the results of the investigation
References
1. Pröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi: 10.1097/WNO.0000000000000642
2. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110
3. Frisch ES, Pretzsch R, Weber MS. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20 – Yet Progress Continues. Neurotherapeutics. 2021 Jul;18(3):1602-22. doi: 10.1007/s13311-02101048-z. Epub 2021 Apr 20.
4. Klein C, Lammens A, SchКfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.
5. Hauser SL, Bar-Or A, Cohen JA, et al. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis from the Pooled Phase 3 ASCLEPIOS I and II Trials. AAN 2020. Poster Session: P7.1-013
6. Kappos L, Bar-Or A, Cohen JA, et al. Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. Annual Meeting of the American Academy of Neurology, 2020.
7. Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):54657. doi: 10.1056/NEJMoa1917246
8. Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018 Jun 12;90(24):e2107-e2118. doi: 10.1212/WNL.0000000000005685. Epub 2018 May 16.
9. Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023 Jul;12(7):e230016. doi: 10.57264/cer-2023-0016. Epub 2023 Jun 2.
10. Chen C, Zhang E, Zhu C, et al. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):8-22.e23. doi: 10.1016/j.japh.2022.07.009. Epub 2022 Aug 1.
11. Hennessy B, Zierhut ML, Kracker H, et al. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Mult Scler Relat Disord. 2022 Aug;64:103908. doi: 10.1016/j.msard.2022.103908. Epub 2022 May 23.
12. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials. Presented at EAN 2020. LB62. Abstracts_LB_210x276_V2.pdf (ean.org). Available from: https://www.ean.org/fileadmin/ user_upload/ean/congress-2020/Present/Abstracts/Abstracts_LB_210x276_V2.pdf
13. De Seze J, Bar-Or A, Correale J, et al. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials. Presented at EAN 2020. LB82
14. Smith P et al. Poster P401 presented at ECTRIMS 2016.
15. Smith P et al. Oral presentation S24-003 presented at AAN 2017.
16. Theil D et al. Poster P657 presented at ECTRIMS 2017.
17. Graham G et al. Poster P0396 presented at ACTRIMSECTRIMS 2020.
18. Savelieva M et al. Poster EP1624 presented at ECTRIMS 2017.
19. Ocrelizumab [prescribing information]. South San Francisco, CA: Genentech; March 2017.
20. Rituximab [summary of product characteristics]. Germany: Roche; February 2020.
21. Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi: 10.3389/fimmu.2022.814064
22. Wu F, Bhansali SG, Law WC, et al. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012 Jul;29(7):1843-53. doi: 10.1007/s11095-012-0708-6
23. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012 Sep;14(3):559-70. doi: 10.1208/s12248-0129367-0. Epub 2012 May 23.
24. Migotto MA et al. P3.406 presented at AAN 2018.
25. Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov;36(11):2986-96. doi: 10.1007/s12325-01901101-6. Epub 2019 Oct 5.
26. Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344-90. doi: 10.1080/10837450902891295
27. Bigaud M, Anthony D, Lutzenburg P, et al. Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised-CD20 Transgenic Mice. Presented at ECTRIMS 2022. P298. Available from: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2022/Abstr acts/P298_Abstract.pdf
28. Hauser S et al. AAN 2022. Oral presentation S14.004.
29. Sacca F et al. EAN 2022. Oral presentation. OPR134.
30. Sacca F et al. Poster presented at ЕAN 2023; EPO-642.
31. Instructions for medical use of drug ofatumumab ЛП-№(001332)-(РГ-RU) dated 10/25/2022. Available from: https://grls.rosminzdrav.ru/grls (accessed 03.11.2022) (In Russ.).
32. Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167. doi: 10.3390/vaccines10122167
Review
For citations:
Popova EV. Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(6):142-145. (In Russ.) https://doi.org/10.14412/2074-2711-2023-6-142-145
Views: 262
Email this article 